

KANSAS SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

General Information

Supplemental rebate offers are accepted:

1. when a class of drugs is initially reviewed by the Preferred Drug List (PDL) Committee for class equivalency
2. when a new drug becomes available for an already established PDL class, or
3. annually during the supplemental rebate review period for an existing PDL class.

New PDL Class or New Drug

New drugs or new PDL classes are reviewed by the PDL Committee. If deemed equivalent and approved for the PDL, supplemental rebate offers for these products must be submitted to the Kansas Department of Health and Environment (KDHE) -Division of Health Care Finance (DHCF) by the close of business on the fifteenth working day after the PDL Committee meeting date. KDHE-DHCF will not accept offers after the fifteenth working day deadline.

Existing PDL Class

Supplemental rebates are reviewed every year for existing PDL drug classes. This is a KDHE-DHCF administrative procedure and the PDL class is not reviewed by the PDL Committee at this time*. See the schedule below. Interested vendors should submit new or amended agreements by the 1st day of the review period (first column).

**Class reviews at the PDL Committee meetings occur only when there is a new agent in the class or when there is new, compelling, peer reviewed data about the class.*

Supplemental Bid Schedule

Bids Due	Contract Period	Drug Class		
January	April - March	Central Nervous System	Non-scheduled Novel Sleep Agents	H8B
		Respiratory	Inhaled Beta 2 Agonists – Long-Acting	B6Y B6Z
		Respiratory	Inhaled Beta 2 Agonists – Short-Acting	B6W
		Gastrointestinal Agents	Oral Mesalamine Products	D6F
		Ophthalmic Agents	Carbonic Anhydrase Inhibitors	Q6G
		Antihyperlipidemics	Hypertriglyceridemia Agents	M4E
		Diabetic Agents	DPP-4 Inhibitors	C4J
February	May – April	Cardiovascular Agents	Beta-Blockers	J7C J7A
		Respiratory	Anti-cholinergics for Maintenance Treatment of COPD	B61 B60
		Central Nervous System	Non-benzodiazepine sedative hypnotics	H2E
		Antihyperlipidemics	HMG-CoA Reductase Inhibitors (Statins)	M4D

KANSAS SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Bids Due	Contract Period	Drug Class		
March	June – May	Cardiovascular Agents	Calcium Channel Blockers (Dihydropyridines)	A9A
		Cardiovascular Agents	Calcium Channel Blockers (Non-Dihydropyridines)	A9A
		Injectables	Erythropoiesis - Stimulating Agents	N1B
		Antihyperlipidemics	Bile Acid Sequestrants	D7L
April	July – June	Osteoporosis Agents	Bisphosphonates	P4L P4N
		Respiratory	Inhaled Corticosteroids	B6M
		Diabetic Agents	Incretin Mimetics	C4I
		Antihyperlipidemics	Homozygous Familial Hypercholesterolemia (HoFH) Agents	M4Q M4R
		Respiratory	Inhaled Tobramycin Products	W1F
		Topical Acne Agents	Topical Acne Agents	L5F L5H L9B L9H Q5S Q5W
		Cardiovascular Agents	Anticoagulants	M9L M9T M9V
		Analgesics	COX-II Inhibitors	S2L
		Testosterone	Topical Testosterone Agents	F1A
		Platelet Aggregation Inhibitors	Platelet Aggregation Inhibitors – Stroke	M9P
		Platelet Aggregation Inhibitors	Platelet Aggregation Inhibitors- Secondary Cardiac Prevention	M6P
		Ophthalmic	Ophthalmic Anti-Infective/Steroid Combinations	Q6S Q6I
		Anti-emetics	Cannabinoid Anti-emetics	H6J
		Urological Agents	Anticholinergics	R1A R1I
May	August – July	Injectables	Growth Hormones	P1A
		Analgesics	Triptans	H3F
		Biologics	Adult Rheumatoid Arthritis Ankylosing Spondylitis Crohn’s Disease Plaque Psoriasis Psoriatic Arthritis	D6A L1A S2J S2M S2Q

KANSAS SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Bids Due	Contract Period	Drug Class		
			Ulcerative Colitis Juvenile Idiopathic Arthritis	S2Z Z2R Z2U Z2V Z2W Z2Z
		Cardiovascular Agents	Angiotensin Receptor Antagonist & Calcium Channel Blocker Combos	A4H
		Anti-Infectives	Topical Lice Treatments	Q5R
		Diabetic Agents	Insulin – Delivery Systems Long Acting Insulin	C4G
		Respiratory	Inhaled Beta 2 Agonists/Corticosteroid – Long-Acting	B63
June	September – August	Diabetic Agents	Biguanides	C4L
		Analgesics	Muscle Relaxants (Skeletal and Spasticity)	H6H
		Allergy Agents	Ophthalmic Antihistamines/Mast Cell Stabilizers	Q6R Q6U
		Allergy Agents	Intranasal Antihistamines	Q7E
July	October - September	Diabetic Agents	Thiazolidinediones	C4N C4R C4T
		Injectables	Injectable Methotrexate	S2N
		Cardiovascular Agents	ARBs	A4F A4I
		Electrolyte Depleters	Phosphate Binder Agents	C1A
		Hematopoietic Agents	Thrombopoietin (TPO) Receptor Agonists	N1F
		Antihyperlipidemics	PCSK-9 Inhibitors	M4T
		Otic Agents	Otic Anti-infective/Steroid combinations	Q8B Q8F Q8W
		Cardiovascular Agents	ACE Inhibitors/Calcium Channel Blocker Combos	A4K
		Analgesics	Long-Acting Opioids	H3A
August	November - October	Gastrointestinal Agents	H2 Antagonists	Z2D
		Analgesics	Non-Steroidal Anti-Inflammatory (NSAIDs) – Ophthalmic, Oral and Topical	S2B Q7K Q6P Q5E H3F S2T S2P H3D

KANSAS SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Bids Due	Contract Period	Drug Class		
		Gastrointestinal Agents	Serotonin 5HT3 Antagonists	H6J
		Gastrointestinal Agents	Pancreatic Enzyme Replacement	D8A
September	December - November	Anti-Infectives	Antiherpes Virus Agents	W5A
		Allergy Agents	Non-Sedating Antihistamines	Z2Q Z2O
		Allergy Agents	Combination Products for Allergic Rhinitis	Q7O
		Nasal Agents	Intranasal Corticosteroids	Q7P
October	January - December	Central Nervous System	Adjunct Antiepileptics	H4B H8R
		Respiratory	Inhaled Long-Acting Beta Agonists/Anticholinergics	B62
		Injectable Agents	Anaphylaxis Agents	J5F
		Ophthalmic Agents	Ophthalmic Prostaglandin Analogs	Q6G
		Anti-Virals	Hepatitis C Antiviral Agents	W0A W0B W0D W0E W5V W5Y
		Gastrointestinal Agents	Opioid-Induced Constipation Agents	H3Y
		Urologic Agents	Beta-3 Adrenergic Agonists	R1V
		Antihyperlipidemics	Combination Products for Hyperlipidemia	M4M
		Diabetic Agents	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors	C4D
		Antihyperlipidemics	Fibric Acid Derivatives	M4E
November	February - January	Diabetic Agents	Meglitinides	C4K
		Diabetic Agents	2nd Generation Sulfonylureas	C4K C4S
		Diabetic Agents	AlphaglucoSIDase Inhibitors	C4M
December	March - February	Cardiovascular Agents	ACE Inhibitors	A4D
		Gout Agents	Xanthine Oxidase Inhibitors	C7A
		Gastrointestinal Agents	Proton Pump Inhibitors	D4J

Step 1: Manufacturer obtains the CMS-approved Supplemental Drug Rebate Agreement and Schedule A (supplemental rebate bid form) at:

http://www.kdheks.gov/hcf/pharmacy/pharmacy_supplemental_rebates.html

September 1, 2016

KANSAS SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Step 2: Manufacturer completes and submits the Supplemental Drug Rebate Agreement and Schedule A.

The manufacturer should complete the contract template/bid form and forward to KDHE-DHCF for review. Bids should be mailed to the following address and must contain two copies of the supplemental drug rebate agreement with actual wet signatures.

KDHE-DHCF
Annette Grant
Landon State Office Building
900 SW Jackson Ave, Suite 900
Topeka, KS 66612

All accepted contracts will guarantee that prior authorization will not be required for one year. If a non-preferred drug(s) becomes less costly than the preferred drug(s), that drug(s) may be moved to the preferred list.

Bid Information Required:

1. 11-digit NDC number
2. Product name, strength and dosage form
3. Pricing reference (WAC)
4. Ingredient reimbursement per unit as outlined on Schedule A
5. CMS rebate per unit as outlined on Schedule A
6. Supplemental offer - Fixed net cost to state per unit

Contact Information Required:

1. Manufacturer name
2. Labeler code(s)
3. Contact name and title
4. Mailing address for contact
5. Telephone, fax, cell phone and voice mail numbers
6. E-mail address

Step 3: KDHE-DHCF will notify manufacturer of acceptance or rejection after the net costs have been calculated.